Lipidomics reveals multiple pathway effects of a multi-components preparation on lipid biochemistry in ApoE*3Leiden.CETP mice

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Wei, Heng ^a,b   Hu, Chunxiu ^c,d   Wang, Mei ^b,e   van den Hoek, Anita M ^a   Reijmers, Theo H ^c,g   Wopereis, Suzan ^a   Bouwman, Jildau ^a,g   Ramaker, Raymond ^a   Korthout, Henrie A A J ^f   Vennik, Marco ^f   Hankemeier, Thomas ^c,g   Havekes, Louis M ^a,h   Witkamp, Renger F ⁱ   Verheij, Elwin R ^a   Xu, Guowang ^b,d   van der Greef, Jan ^a,b,c,e  

^a TNO   (Netherlands)

^b Sino Dutch Centre for Preventive and Personalized Medicine   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^e SU BioMedicine   (Netherlands)

^f FYTAGORAS BV   (Netherlands)

^g LEIDEN UNIVERSITY   (Netherlands)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN E3; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RIMONABANT; SUB 885C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; HERBACEOUS AGENT; HYPOCHOLESTEROLEMIC AGENT; LIPID; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; SUB885C;

ADIPOCYTE; ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; FEEDING BEHAVIOR; FEMALE; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; LIPID ANALYSIS; LIPID COMPOSITION; LIPID DEGRADATION; LIPID STORAGE; LIPIDOMICS; LIVER LEVEL; METABOLIC REGULATION; METABOLIC SYNDROME X; MOUSE; NONHUMAN; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WEIGHT REDUCTION; ANIMAL; BODY WEIGHT; CELL STRAIN 3T3; CHEMISTRY; GENETICS; LIPID METABOLISM; METABOLISM; METABOLOMICS; METHODOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALIA; MUS;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN E3; BIOCHEMISTRY; BODY WEIGHT; CHOLESTEROL ESTER TRANSFER PROTEINS; DRUG EVALUATION, PRECLINICAL; DRUGS, CHINESE HERBAL; FEMALE; LIPID METABOLISM; LIPIDS; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; MICE; MICE, TRANSGENIC; PIPERIDINES; PYRAZOLES;

EID: 84856112746     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030332     Document Type: Article

References (53)

1. Anand SS, Yusuf S, (2011) Stemming the global tsunami of cardiovascular disease. The Lancet 377: 529-532.
2. James WPT, (2008) The epidemiology of obesity: The size of the problem. Journal of Internal Medicine 263: 336-352.
3. Cannon CP, (2009) Can the polypill save the world from heart disease? The Lancet 373: 1313-1314.
4. Lonn E, Yusuf S, (2009) Polypill: the evidence and the promise. Current Opinion in Lipidology 20: 453-459.
5. Franco OH, Bonneux L, De Laet C, Peeters A, Steyerberg EW, et al. (2004) The Polymeal: A more natural, safer, and probably tastier (than the Polypill) strategy to reduce cardiovascular disease by more than 75%. British Medical Journal 329: 1447-1450.
6. Chau CF, Wu SH, (2006) The development of regulations of Chinese herbal medicines for both medicinal and food uses. Trends in Food Science and Technology 17: 313-323.
7. Wang M, Lamers RJAN, Korthout HAAJ, Van Nesselrooij JHJ, Witkamp RF, et al. (2005) Metabolomics in the context of systems biology: Bridging Traditional Chinese Medicine and molecular pharmacology. Phytotherapy Research 19: 173-182.
8. Bernatoniene J, Thrumbeckaite S, Majiene D, Baniene R, Baliutyte G, et al. (2009) The effect of crataegus fruit extract and some of its flavonoids on mitochondrial oxidative phosphorylation in the heart. Phytotherapy Research 23: 1701-1707.
9. Feng Y, Huang S, Dou W, Zhang S, Chen J, et al. (2010) Emodin, a natural product, selectively inhibits 11β-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice. British Journal of Pharmacology 161: 113-126.
10. Ng TB, Gao W, Li L, Niu SM, Zhao L, et al. (2005) Rose (Rosa rugosa)-flower extract increases the activities of antioxidant enzymes and their gene expression and reduces lipid peroxidation. Biochemistry & Cell Biology 83: 78-85.
11. Tadić VM, Dobrić S, Marković GM, D{stroke}ord{stroke}ević SM, Arsić IA, et al. (2008) Anti-inflammatory, Gastroprotective, Free-Radical-Scavenging, and Antimicrobial Activities of Hawthorn Berries Ethanol Extract. Journal of Agricultural and Food Chemistry 56: 7700-7709.
12. Tian WX, Li LC, Wu XD, Chen CC, (2004) Weight reduction by Chinese medicinal herbs may be related to inhibition of fatty acid synthase. Life Sciences 74: 2389-2399.
13. de Haan W, de Vries-van der Weij J, Mol IM, Hoekstra M, Romijn A, et al. (2009) PXR agonism decreases plasma HDL levels in ApoE*3-Leiden.CETP mice. Biochimica et Biophysica Acta (BBA)- Molecular and Cell Biology of Lipids 1791: 191-197.
14. de Haan W, de Vries-van der Weij J, van der Hoorn JWA, Gautier T, van der Hoogt CC, et al. (2008) Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin. Circulation 117: 2515-2522.
15. de Haan W, van der Hoogt CC, Westerterp M, Hoekstra M, linga-Thie GM, et al. (2008) Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis 197: 57-63.
16. Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, linga-Thie GM, et al. (2006) Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice. Arteriosclerosis, Thrombosis, and Vascular Biology 26: 2552-2559.
17. van der Hoorn JWA, Jukema JW, Havekes LM, Lundholm E, Camejo G, et al. (2009) The dual PPAR α/γ agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. British Journal of Pharmacology 156: 1067-1075.
18. van Vlijmen BJ, van den Maagdenberg AM, Gijbels MJ, van der Boom H, HogenEsch H, et al. (1994) Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. The Journal of Clinical Investigation 93: 1403-1410.
19. Zadelaar S, Kleemann R, Verschuren L, de Vries-van der Weij J, van der Hoorn J, et al. (2007) Mouse Models for Atherosclerosis and Pharmaceutical Modifiers. Arteriosclerosis, Thrombosis, and Vascular Biology 27: 1706-1721.
20. German JB, Gillies LA, Smilowitz JT, Zivkovic AM, Watkins SM, (2007) Lipidomics and lipid profiling in metabolomics. Current Opinion in Lipidology 18: 66-71.
21. Nishina PM, Verstuyft J, Paigen B, (1990) Synthetic low and high fat diets for the study of atherosclerosis in the mouse. Journal of Lipid Research 31: 859-869.
22. Niwano Y, Beppu F, Shimada T, Kyan R, Yasura K, et al. (2009) Extensive Screening for Plant Foodstuffs in Okinawa, Japan with Anti-Obese Activity on Adipocytes In Vitro. Plant Foods for Human Nutrition (Formerly Qualitas Plantarum) 64: 6-10.
23. Ramírez-Zacarías JL, Castro-Muñozledo F, Kuri-Harcuch W, (1992) Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with oil red O. Histochemistry and Cell Biology 97: 493-497.
24. Dullaart RP, Riemens SC, Scheek LM, van Tol A, (1999) Insulin decreases plasma cholesteryl ester transfer but not cholesterol esterification in healthy subjects as well as in normotriglyceridaemic patients with type 2 diabetes. European Journal of Clinical Investigation 29: 663-671.
25. Hu C, van Dommelen J, van der Heijden R, Spijksma G, Reijmers TH, et al. (2008) RPLC-Ion-Trap-FTMS Method for Lipid Profiling of Plasma: Method Validation and Application to p53 Mutant Mouse Model. Journal of Proteome Research 7: 4982-4991.
26. Bligh E, WJ D, (1959) A rapid method of total lipid extraction and purification. Canadian Journal of Biochemistry and Physiology 37: 911-917.
27. van der Greef J, Martin S, Juhasz P, Adourian A, Plasterer T, et al. (2007) The Art and Practice of Systems Biology in Medicine:ΓÇë Mapping Patterns of Relationships. Journal of Proteome Research 6: 1540-1559.
28. van der Kloet FM, Bobeldijk I, Verheij ER, Jellema RH, (2009) Analytical Error Reduction Using Single Point Calibration for Accurate and Precise Metabolomic Phenotyping. Journal of Proteome Research 8: 5132-5141.
29. Wopereis S, Rubingh CM, van Erk MJ, Verheij ER, van Vliet T, et al. (2009) Metabolic Profiling of the Response to an Oral Glucose Tolerance Test Detects Subtle Metabolic Changes. PLoS ONE 4: e4525.
30. Bijlsma S, Bobeldijk I, Verheij ER, Ramaker R, Kochhar S, et al. (2005) Large-Scale Human Metabolomics Studies: A Strategy for Data (Pre-) Processing and Validation. Analytical Chemistry 78: 567-574.
31. Vandeginste B, Massart D, Buydens L, De Jong S, Lewi PJ, et al. (1998) Handbook of Chemometrics and Qualimetrics: Part B Amsterdam Elsevier.
32. Barker M, Rayens W, (2003) Partial least squares for discrimination. Journal of Chemometrics 17: 166-173.
33. Smit S, van Breemen MJ, Hoefsloot HCJ, Smilde AK, Aerts JMFG, et al. (2007) Assessing the statistical validity of proteomics based biomarkers. Analytica Chimica Acta 592: 210-217.
34. Hu C, Wei H, van den Hoek AM, Wang M, van der Heijden R, et al. (2011) Plasma and Liver Lipidomics Response to an Intervention of Rimonabant in ApoE*3Leiden.CETP Transgenic Mice. PLoS ONE 6: e19423.
35. Anthonsen MW, Rönnstrand L, Wernstedt C, Degerman E, Holm C, (1998) Identification of Novel Phosphorylation Sites in Hormone-sensitive Lipase That Are Phosphorylated in Response to Isoproterenol and Govern Activation Properties in Vitro. Journal of Biological Chemistry 273: 215-221.
36. Chui SH, Chow FC, Chan K, Fu S, Szeto YT, (2008) Slimpid may boost plasma IGF-1 level and improve the quality of life in patients with risk of developing metabolic syndrome. Journal of Complementary and Integrative Medicine 5: number 17.
37. Grover JK, Yadav S, Vats V, (2002) Medicinal plants of India with anti-diabetic potential. Journal of Ethnopharmacology 81: 81-100.
38. Liu JP, Zhang M, Wang WY, Grimsgaard S, (2004) Chinese herbal medicines for type 2 diabetes mellitus. Cochrane database of systematic reviews (Online) pp. CD003642.
39. Van Wietmarschen H, Yuan K, Lu C, Gao P, Wang J, et al. (2009) Systems biology guided by Chinese medicine reveals new markers for sub-typing rheumatoid arthritis patients. Journal of Clinical Rheumatology 15: 330-337.
40. Verpoorte R, Crommelin D, Danhof M, Gilissen LJWJ, Schuitmaker H, et al. (2009) Commentary: "A systems view on the future of medicine: Inspiration from Chinese medicine?". Journal of Ethnopharmacology 121: 479-481.
41. Witkamp RF, (2010) Biologically Active Compounds in Food Products and Their Effects on Obesity and Diabetes Oxford Elsevier.
42. Yuliana ND, Iqbal M, Jahangir M, Wijaya CH, Korthout H, et al. (2011) Screening of selected Asian spices for anti obesity-related bioactivities. Food Chemistry 126: 1724-1729.
43. de Vries-van der Weij J, Zadelaar S, Toet K, Havekes LM, Kooistra T, et al. (2009) Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice. Atherosclerosis 206: 153-158.
44. van der Hoorn JWA, de Haan W, Berbee JFP, Havekes LM, Jukema JW, et al. (2008) Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice. Arteriosclerosis, Thrombosis, and Vascular Biology 28: 2016-2022.
45. Jones D, (2008) End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov 7: 961-962.
46. Mitchell PB, Morris MJ, (2007) Depression and anxiety with rimonabant. The Lancet 370: 1671-1672.
47. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, et al. (2007) Effects of Torcetrapib in Patients at High Risk for Coronary Events. New England journal of medicine 357: 2109-2122.
48. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M, (2007) PPAR dual agonists: Are they opening Pandora's Box? Pharmacological Research 56: 91-98.
49. Witkamp RF, (2011) Current and Future Drug Targets in Weight Management. Pharmaceutical Research 28: 1792-1818.
50. Despres JP, Golay A, Sjostrom L, (2005) Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia. The New England Journal of Medicine 353: 2121-2134.
51. Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, et al. (2008) Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease: The STRADIVARIUS Randomized Controlled Trial. JAMA: The Journal of the American Medical Association 299: 1547-1560.
52. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S, (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. The Lancet 365: 1389-1397.
53. Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, et al. (2006) The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Cell Proliferation and Increases Markers of Adipocyte Maturation in Cultured Mouse 3T3 F442A Preadipocytes. Molecular Pharmacology 69: 471-478.